| 000 | 01724 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516084832.0 | ||
| 264 | 0 | _c20130619 | |
| 008 | 201306s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2012.682311 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWalter, Eva | |
| 245 | 0 | 0 |
_aRituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cNov 2012 |
||
| 300 |
_a2290-2 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntigens, CD20 _xanalysis |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBendamustine Hydrochloride |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNitrogen Mustard Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aPrednisone _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aVincristine _xtherapeutic use |
| 700 | 1 | _aSchmitt, Thomas | |
| 700 | 1 | _aDietrich, Sascha | |
| 700 | 1 | _aHo, Anthony | |
| 700 | 1 | _aWitzens-Harig, Mathias | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 53 _gno. 11 _gp. 2290-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2012.682311 _zAvailable from publisher's website |
| 999 |
_c21677581 _d21677581 |
||